Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

NCT06806930 is registered in ClinicalTrials.gov with George Washington University as lead sponsor.

NCT NCT06806930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06806930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
Lead sponsor
George Washington University
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2024
Completion date
October 31, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage i, breast cancer stage ii, breast cancer stage iii, carcinoma, breast